• Portfolio
  • Latest Articles

PSYCHEDELICS

June 11th

CPH to expand US footprint after USOTC listing

  Archived
Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

June 8th 2021

Creso’s acquisition target Halucenex to extend clinical trials beyond veterans

Bill passed: wide range of psychedelics could be made legal in the US

June 3rd 2021

Bill passed: wide range of psychedelics could be made legal in the US

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

May 26th 2021

Creso Pharma’s Halucenex engages HeteroGeneity ahead of US entry

CPH further derisks acquisition as Halucenex adds to its psychedelics supply

May 14th 2021

CPH further derisks acquisition as Halucenex adds to its psychedelics supply

Halucenex forms important partnership as psychedelics space heats

May 6th 2021

Halucenex forms important partnership as psychedelics space heats

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

April 30th 2021

Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing

Move to legalisation of psychedelics could benefit CPH in the US

April 19th 2021

Move to legalisation of psychedelics could benefit CPH in the US

Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds

April 12th 2021

Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds

Page 1 of 2 next >

Connect with us

EXPLORE

  • Finfeed Portfolio
  • Latest Articles
  • How It Works
  • Archived Articles
  • About StocksDigital
  • News
  • PORTFOLIOS

  • Next Investors
  • Catalyst Hunter
  • Wise-Owl
  • STOCKS

    FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS
      CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY  
    The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
    © 2021   |   AFSL (CAR No.433913)